Anders Martin-Löf has been appointed new Chief Financial Officer of Oncopeptides and he will join the company in November.
CFO Birgitta Ståhl has decided to step down as the CFO as the company expands the organization in Europe and the US, following a preparation and execution of Oncopeptides’ IPO. She will continue to work in the company.
Anders has extensive life science experience in financial, strategic and commercial positions in both public and private entities. The last decade he has been the CFO of Raysearch and Wilson Therapeutics. During this period Raysearch developed a global commercial footprint and Wilson Therapeutics went public on Nasdaq OMX and later acquired by Alexion. Anders brings broad knowledge from companies with international presence and his experience will be important to further develop the Oncopeptides organization.
“We are looking forward to Anders joining Oncopeptides and its management team. He will have an important operational and strategic role in the company given our agenda as a company” said Jakob Lindberg, CEO of Oncopeptides.